Interleukin-10 (IL-10) has been described as an anti-inflammatory cytokine and B-cell proliferation factor and has been implicated in autoimmunity, tumorigenesis and transplantation tolerance. We have identified three single base pair substitutions in the IL-10 gene promoter and have investigated whether this polymorphism correlates with IL-10 protein production in vitro.
"Three biallelic single-nucleotide polymorphisms (SNPs) were described in the promoter region -1082 (G/A), -819 (C/T) and -592 (C/A). There is linkage disequilibrium between the SNPs -819 and -592 because the C allele of -819 is always present when there is a C allele in -592, whereas the T allele is always present in -819 when the A allele is in -592  . "
"IL-10 gene promoter and intron polymorphisms as genetic biomarkers of cervical cancer susceptibility among Tunisians. Cytokine (2015), http://dx.doi.org/10.1016/j.cyto.2015.05.028 has been reported that several important polymorphic sites in the IL-10 gene, appears to be responsible with modulated levels of IL-10   . The association of IL-10 promoter SNPs with CC has been reported by several studies, but with inconclusive findings     . "
"The human gene encoding IL-10 is located on chromosome 1 (1q31–1q32) and spans about 4.7 kb (Turner et al., 1997). The IL-10 gene promoter is highly polymorphic and the polymorphisms have been associated with diseases by regulating the transcription of IL-10 RNA and the expression of IL-10. "
[Show abstract][Hide abstract] ABSTRACT: Previous studies investigated the associations of interleukin-10 (IL-10) polymorphisms with different types of cancer, indicating an influence on cancer risk. IL-10-3575T>A (rs1800890) has been studied concerning a potential implication in terms of some cancer site risks, but the results from single studies are contradictory.
Eligible articles were identified by a search of the PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) databases until November 30, 2014. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the cancer risk by cancer sites, ethnicity, and other study features.
We identified 15 published studies to research the link of the IL-10-3575T>A polymorphism with cancer risk. Our meta-analysis indicated that the IL-10-3575T>A polymorphism has a significant association with decreased melanoma risk in the heterozygote model (OR=0.67, 95% CI=0.49-0.92, p=0.02) and dominant model (OR=0.70, 95% CI=0.52-0.95, p=0.01), but increased diffuse large B-cell lymphoma (DLBCL) risk in all the different genetic models.
Our analysis suggests that the IL-10-3575T>A mutation may associate with melanoma and DLBCL and exert a differential effect in different cancer sites. However, other factors may influence the association, and large-scale multicenter with adequate methodological quality studies are needed to confirm the impact on cancer susceptibility.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.